Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Viracta Therapeutics Inc (VIRX)

Viracta Therapeutics Inc (VIRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,720
  • Shares Outstanding, K 38,197
  • Annual Sales, $ 0 K
  • Annual Income, $ -114,760 K
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.21
Trade VIRX with:

Options Overview Details

View History
  • Implied Volatility 122.49% ( +74.25%)
  • Historical Volatility 80.13%
  • IV Percentile 78%
  • IV Rank 24.47%
  • IV High 429.50% on 12/27/21
  • IV Low 23.05% on 05/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,424
  • Open Int (30-Day) 1,389

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.50
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -29.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8200 +3.30%
on 12/08/22
3.6350 -48.28%
on 11/09/22
-1.8100 (-49.05%)
since 11/08/22
3-Month
1.8200 +3.30%
on 12/08/22
5.7500 -67.30%
on 09/16/22
-3.4100 (-64.46%)
since 09/08/22
52-Week
1.8200 +3.30%
on 12/08/22
5.7500 -67.30%
on 09/16/22
-2.4800 (-56.88%)
since 12/08/21

Most Recent Stories

More News
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession...

VIRX : 1.8800 (-2.59%)
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?

Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.

IMRA : 3.75 (+0.54%)
VIRX : 1.8800 (-2.59%)
Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?

The consensus price target hints at a 334.8% upside potential for Sunesis (VIRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

VIRX : 1.8800 (-2.59%)
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

CPRX : 16.79 (-0.18%)
AERI : 15.25 (+0.07%)
SLNO : 0.9400 (-1.82%)
VIRX : 1.8800 (-2.59%)
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the...

VIRX : 1.8800 (-2.59%)
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s)...

VIRX : 1.8800 (-2.59%)
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year

Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.

SLNO : 0.9400 (-1.82%)
ASRT : 3.58 (+4.07%)
KDNY : 23.40 (-0.59%)
VIRX : 1.8800 (-2.59%)
Here's Why Assertio Holdings (ASRT) Stock is Up This Year

Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.

SLNO : 0.9400 (-1.82%)
ASRT : 3.58 (+4.07%)
KDNY : 23.40 (-0.59%)
VIRX : 1.8800 (-2.59%)
Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics

Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.

SLNO : 0.9400 (-1.82%)
ASRT : 3.58 (+4.07%)
KDNY : 23.40 (-0.59%)
VIRX : 1.8800 (-2.59%)
4 Small Stocks to Bet on in an Upbeat Drugs Industry

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

KDNY : 23.40 (-0.59%)
SLNO : 0.9400 (-1.82%)
ASRT : 3.58 (+4.07%)
VIRX : 1.8800 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Viracta Therapeutics Inc. is a precision oncology company targeting virus-associated malignancies. The company is pursuing application of inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other virus-related cancers. Viracta...

See More

Key Turning Points

3rd Resistance Point 2.2367
2nd Resistance Point 2.1433
1st Resistance Point 2.0367
Last Price 1.8800
1st Support Level 1.8367
2nd Support Level 1.7433
3rd Support Level 1.6367

See More

52-Week High 5.7500
Fibonacci 61.8% 4.2487
Fibonacci 50% 3.7850
Fibonacci 38.2% 3.3213
Last Price 1.8800
52-Week Low 1.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar